Hitendra Patel, MD

Assistant Professor, Medicine
Phone Number: 
(520) 694-2873
(520) 626-2225
Patient Appointments: 
(520) 694-2873
Professional Bio: 

Dr. Patel is a Gastrointestinal (GI) Medical Oncologist and an Assistant Professor at University of Arizona College of Medicine and specializes in treatment of gastrointestinal cancers and skin cancers. As a GI medical oncologist, he manages patients with gastrointestinal malignancies.

Dr. Patel is the team leader of the Gastrointestinal Cancer Research Team at the University of Arizona Cancer Center. This team is comprised of other medical oncologists/NPs, GI surgeons, radiation oncologists and other research staff which includes nurses and clinical coordinators. This team plays a critical role in the development of the investigator initiated GI oncology clinical trials, evaluate new trials to be opened at UACC, monitor ongoing trials for accrual and regulatory compliance.

Dr. Patel is also site-PI for many national and international oncology clinical trials and as such he oversee all aspects of the clinical trial coordination at University of Arizona Cancer Center including screening, accrual, retention, data acquisition, biospecimen acquisition. He holds regular meetings and discussions with investigators and staff to ensure that barriers or challenges are identified early and addressed appropriately.

Dr. Patel was a member of the data safety monitoring team for the University of Kansas Medical center. He is currently the Chair of Data Safety monitoring Board at UACC.

Dr. Patel has been involved in translational research and was awarded peer reviewed grant for a translational research project titled “Metabolic flux and anti-metabolite drug combinations in pancreatic cancer” in April 2015. He is involved in GI SPORE (P50- NCI) grant application at University of Arizona Cancer Center as a co-investigator in one project.

Dr. Patel is board certified in Internal Medicine, Hematology and Oncology and has more than 10 years of experience treating these cancers. After finishing his Fellowship in Hematology and Oncology in 2005, he was faculty at University of Missouri-Kansas City School of Medicine (UMKC). At UMKC he mentored many medical students, Internal Medicine residents and Hematology/Oncology Fellows. He was Program Director of Hematology/Oncology Fellowship Program and Chair of Oncology Committee at UMKC in Kansas City.

He joined University of Arizona Cancer Center in 2012 and has been active in cancer treatment and research. He leads the research team focused on treatment and research of Gastrointestinal Cancer. He is the Chair of Data Safety Monitory Committee at the University of Arizona Cancer Center, which oversees issues related to safety of subjects involved in cancer clinical trials.

Dr. Patel’s goal is to achieve the best possible outcome in management of cancer while preserving quality of life. He is known to be a compassionate physician who spend as much time as it is needed to address any issue which arises during cancer treatment.

Medical Oncology

Clinical Information

Clinical Focus: 

Click here to see a list of Dr. Patel's active clinical trials.

Disease or Clinical Specialty: 
Anal Cancer
Bile Duct Cancer
Cancer Prevention
Carcinoid Tumor
Colon-Colorectal Cancer
Esophageal Cancer
Gastric Cancer
Gastrointestinal Stromal Tumor
Large Intestines
Liver Cancer
Pancreatic Cancer
Rectal Cancer
Solid Tumors
Stomach Cancer
Unknown Primary

Research Information

Research Program: 
Therapeutic Development
Member Status: 
Research Member
Selected Publications: 

Book Chapter:

  1. Cantoria MJ, Patel H, Boros LG and Meuillet MJ; “Metformin and Pancreatic Cancer Metabolism” in Book titled “Pancreatic Cancer - Insights into Molecular Mechanisms and Novel Approaches to Early Detection and Treatment,” book edited by Dr. Kelly McCall, ISBN: 978-953-51-1375-1, Published May 2014

Journal Articles:

  1. Jacobs SA, Vidnovic N, Patel H, Soma LA, Chang Y, Bass N, Swerdlow SH; “Durable remission of HIV-negative, Kaposi’s sarcoma herpes virus-associated multicentric          Castleman disease in patient with rheumatoid arthritis treated with methotrexate’’ ; Clin Rheumatol, 2006 Jul 6 
  2. Patel H, Stoller R, Auber M, Potter D, Cai C, Zamboni W, Kiefer G, Matin K, Schmotzer A, Ramanathan RK; “Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy”; Invest New Drugs, 2006 Jul; 24 (4): 359-63
  3. Patel C, Jennings WH, Patel, H; “Laboratory Evaluation of Thrombophilia”; Missouri Medicine, January/February 2009; Vol. 106, Number 1: 55-59
  4. Haideri N, Patel H; “New Anticoagulants & Clinical Trials”, Missouri Medicine, January/February 2009; Vol. 106, Number 1: 60-64
  5. Samulitis BK, Pond K, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH. "Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther. 2014 Dec 8:0. [Epub ahead of print]
  6. Malangone S, Patel H, Kurtin SE, Tiwari HA, and Elquza, E, MD. Management of the Patient With Metastatic Colorectal Adenocarcinoma. J Adv Pract Oncol 2015;6:144–152 

Professional Information

Other Experience and Professional Memberships/Affiliations: 

American Society of Clinical Oncology
American Society of Hematology
South Western Oncology Group (SWOG)

Board Certifications: 

Medical Oncology
Internal Medicine

Academic Information

University of Pittsburgh
University of Pittsburgh
Medical School: 
M.G.M. Medical College, Indore, India